

Substitute for form 1449B/PTO

STATEMENT BY APPLICANT

MAR 29 2006
Use as many sheets as possible
PATENT & TRADEMARK OFFICE

(use as many sheets as necessary)

Sheet

of

1

Application Number

10/507,237

Filing Date

September 9, 2004

First Named Inventor

Emini, Emilio A. et al.

Group Art Unit

1648

Examiner Name

Attorney Docket Number

21051 YP

**Examiner
Initials***

Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

/BB/

Pinto, A. et al. "Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers", The Journal of Immunology, 2003, Vol. 171, pp. 6774-6779

/BB/

Moffatt, S. et al. "Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non-Human Adenoviruses: Implications in Gene Therapy", *Virology*, 2000, Vol. 272, pp. 159-167

/BB/

Ramshaw, I. et al. "The prime-boost strategy: exciting prospects for improved vaccination", Trends Immunology Today, 2000, Vol. 21, pp. 163-165

**Examiner
Signature**

/Benjamin Blumel/

Date Considered

06/15/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use ~~as~~ many sheets as necessary)

of

2

10/507,237

September 9, 2004

Emini, Emilio A. et al.

21051YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/BB/		WO	04/037294		Crucell Holland B.V.	05/06/2004
		WO	03/031588		Merck & Co., Inc.; Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.	04/17/2003
		WO	02/022080		Merck & Co., Inc.	03/21/2002
		WO	01/02607		Merck & Co., Inc.	01/11/2001
		WO	00/70071		Introgene B.V.	11/23/2000
/BB/		WO	96/21015		Chiron Viagene, Inc.	07/11/1996

/Benjamin Blumel/

06/15/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 309. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

COMPLETE IF KNOWN

Application Number	10/507,237
Filing Date	September 9, 2004
First Named Inventor	Emini, Emilio A. et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21051YP

(use many sheets as necessary)

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/BB/		Barnett, S. et al. "Prime-Boost Immunization Strategies against HIV", AIDS Research and Human Retroviruses, 1998, Vol. 14, Supplement 3, pp. S-299-S-309
		Chen, P. et al. "Effective repeat administration with adenovirus vectors to the muscle", Gene Therapy, 2000, Vol. 7, pp. 587-595
		Huang, Y. et al. "Human Immunodeficiency Virus Type 1-Specific Immunity after Genetic Immunization Is Enhanced by Modification of Gag and Pol Expression", Journal of Virology, 2001, Vol. 75, pp. 4947-4951
		Mack, C. et al. "Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype", Human Gene Therapy, 1997, Vol. 8, pp. 99-109
		Mastrangeli, A. et al. "'Sero-Switch' Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype", Human Gene Therapy, 1996, Vol. 7, pp. 79-87
		Morral, N. et al. "Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons", Proc. Natl. Acad. Sci. USA, 1999, Vol. 96, pp. 12816-12821
		Nan, X. et al. "Development of an Ad7 cosmid system and generation of an Ad7DE13HIVDmn env/rev recombinant virus", Gene Therapy, 2003, Vol. 10, pp. 326-336
		Natuk, R. et al. "Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model", Proc. Natl. Acad. Sci., USA, 1992, Vol. 89, pp. 7777-7781
		Natuk, R. et al. "Adenovirus Vectored Vaccines", Developments in Biological Standardization, 1994, Vol. 82, pp. 71-77
		Natuk, R. et al. "Immunogenicity of Recombinant Human Adenovirus-Human Immunodeficiency Virus Vaccines in Chimpanzees", AIDS Research and Human Retroviruses, 1993, Vol. 9, pp. 395-404
		Patterson, L. et al. "Potent, Persistent Cellular Immune Responses Elicited by Sequential Immunization of Rhesus Macaques with Ad5 Host Range Mutant Recombinants Encoding SIV Rev and SIV Nef", DNA and Cell Biology, 2002, Vol. 21, pp. 627-635
		Shiver, J. et al. "Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity", Nature, 2002, Vol. 415, pp. 331-335
/BB/		Yoshida, T. et al. "Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols", Clin. Exp. Immunol., 2001, Vol. 124, pp. 445-452

Examiner Signature

/Benjamin Blumel/

Date Considered

06/15/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/03/2003